For people with chronic knee osteoarthritis who aren’t ready for — or aren’t good candidates for — total knee replacement, a minimally invasive procedure called genicular artery embolization, or GAE, is emerging as a middle path between injections and surgery.
The outpatient procedure works by threading a thin catheter into the small arteries that supply the knee joint and selectively blocking abnormal blood vessel growth that forms in response to inflammation. Interventional radiologists believe this excess, disorganized blood vessel growth — known as neovascularization — feeds ongoing inflammation and contributes to persistent pain, and that reducing it can calm the joint down without removing or replacing any tissue.
Research on the technique has accelerated over the past two years. A systematic review published this year in the Journal of Vascular and Interventional Radiology pooled data from 14 studies covering 510 patients and 567 treated knees, including three sham-controlled randomized trials. It found GAE produced a pooled pain reduction of roughly 30 points on a 100-point pain scale at six to twelve months, with corresponding improvements in standard function scores used to assess osteoarthritis severity.
A separate, sham-controlled systematic review covering 138 patients found particularly strong short-term results — one trial recorded a drop in pain scores of more than 50 points within a single month, compared to essentially no change in the placebo group. Researchers caution, though, that results across studies have been mixed, and that the strong placebo response seen in some trials makes it harder to isolate exactly how much of the benefit comes from the procedure itself.
A retrospective study of 236 patients at the University of California, Los Angeles, which looked at who benefits most from the procedure, found that earlier intervention was associated with better outcomes — reinforcing the idea that GAE may be most useful for patients with moderate disease who have exhausted conservative treatments like physical therapy and injections but aren’t yet at the point of needing a joint replacement.
The procedure isn’t without limitations. Most of the supporting evidence so far comes from single-arm studies without comparison groups, and researchers describe the sham-controlled trial data as still “mixed.” Larger, longer-term randomized trials — several of which are now underway at academic medical centers in the U.S. and Europe — will be needed to determine how durable the pain relief is and which patients are the best candidates.
Even so, doctors say the early data offers a genuinely new option for a population that has had few choices beyond injections, physical therapy, and surgery. For patients hoping to stay active — gardening, cycling, or simply walking without pain — GAE represents a chance to delay or potentially avoid knee replacement altogether while researchers continue to refine exactly who stands to benefit most.
